Healthcare & Life Sciences

HRS9531 Phase 3 Trial Beijing, Cardiovascular Disease

A Phase 3 clinical trial for HRS9531, an investigational treatment for cardiovascular disease, has been registered on ClinicalTrials.gov. The trial is being conducted in Beijing. No additional details regarding enrollment, endpoints, or study timeline are available in this registration entry.

Proceade-CRC-03: Two Drug Regimens for Metastatic Colorectal Cancer

ClinicalTrials.gov has registered Proceade-CRC-03 (NCT07549412), a Phase 3 clinical trial evaluating two drug regimens for the treatment of metastatic colorectal cancer. The trial is catalogued under Phase 3 studies sorted by start date. This entry provides standardized trial information for public and researcher access, including study objectives, participant eligibility criteria, and anticipated endpoints.

Tiaoshen Anti-Cancer Protocol, Ovarian Cancer, Insomnia, Shanghai

A Phase 3 clinical trial (NCT07550205) titled 'Tiaoshen Anti-Cancer Protocol' has been registered on ClinicalTrials.gov for the investigation of ovarian cancer and insomnia. The trial is conducted in Shanghai. ClinicalTrials.gov serves as a public registry for clinical studies, providing basic trial information including conditions studied, location, and registration identifiers.

Phase 3 Trial of Phosphate Replacement Fluid for AKI CRRT Sepsis Patients in China

A Phase 3 clinical trial (NCT07550894) evaluating phosphate replacement fluid for critically ill patients with acute kidney injury undergoing continuous renal replacement therapy and sepsis has been registered on ClinicalTrials.gov. The trial is conducted in China and represents an interventional study focused on electrolyte management in severe kidney injury. This is a standard clinical trial registration entry providing public transparency on ongoing research.

Phase 3 Electroacupuncture Study, Chronic Consciousness Disorders

A Phase 3 clinical trial investigating electroacupuncture as an intervention for chronic consciousness disorders has been registered in ClinicalTrials.gov under identifier NCT07551076. The trial is listed in the Phase 3 subset of studies sorted by start date on the NIH clinical research registry. This registration provides public accountability for the conduct of this interventional study involving electrical stimulation of acupuncture points.

Phase 3 Neuroblastoma Trial With hu14 Antibody

A Phase 3 clinical trial evaluating hu14 antibody for neuroblastoma has been registered on ClinicalTrials.gov. The trial is listed as recruiting participants and includes standard registry information on study design and eligibility criteria. This entry provides public visibility into ongoing late-stage oncology research.

Phase 3 Rectal Cancer Clinical Trial NCT07551479 Shanghai

A Phase 3 clinical trial for rectal cancer has been registered in ClinicalTrials.gov (NCT07551479) and is listed by start date. The trial is being conducted in Shanghai and represents a newly added Phase 3 clinical research study in the registry database.

SCRT, Chemo, Immuno-neoadjuvant Therapy, Rectal Adenocarcinoma, Guangzhou, Phase III

A Phase III clinical trial investigating short-course radiotherapy (SCRT) combined with chemotherapy and immuno-neoadjuvant therapy for rectal adenocarcinoma is registered on ClinicalTrials.gov under NCT07549399. The trial is being conducted in Guangzhou, China, and is currently listed in the ClinicalTrials.gov Phase III registry sorted by start date. No specific enrollment, completion dates, or regulatory compliance details are provided in this database entry.

Etoricoxib, Diacerein, Osteoarthritis Pain, 3 Mexican Cities

NCT07549386 is a Phase 3 clinical trial registered on ClinicalTrials.gov evaluating etoricoxib and diacerein for the treatment of osteoarthritis pain. The study is being conducted across three cities in Mexico. No additional study details, enrollment figures, or start dates are provided in the source record.

CD20 Inhibitors and Bisfluoroalkyl-1,4-Benzodiazepinone Compounds - EP3790553A1

EPO published patent application EP3790553A1 for compositions comprising CD20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use, filed by Ayala Pharmaceuticals Inc. The application names Roni MAMLUK as inventor and covers pharmaceutical compositions for therapeutic use, with A61P 35/00 classification indicating oncology applications. The designated states include all EPC contracting states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR).

Cell Penetrating Peptides and Uses Thereof, Entrada Therapeutics, EP3613426A1

Entrada Therapeutics, Inc. filed European patent application EP3613426A1 for cell penetrating peptides on April 15, 2026, covering therapeutic uses including treatments for cancer (A61P35/00), diabetes (A61P3/10), and kidney disease (A61P13/00). The application is classified under multiple IPC codes including C07K7/06, A61K38/00, A61K38/05, A61K38/12, A61K38/46, and A61K47/64, with inventors named as PEI, Dehua and QIAN, Ziqing. The application designates multiple European states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

MMP-1 Antisense Oligonucleotides, Olipass, Published Apr 15

Olipass Corporation has obtained publication of European patent application EP3794124A1 for matrix metalloproteinase-1 (MMP-1) antisense oligonucleotides, a therapeutic compound class for dermatological applications. The application was published April 15, 2026 under IPC classification C12N 15/113 with priority filing established. The patent names six inventors and designates 31 contracting states across the European patent system.

Cladribine Regimen for Treating Progressive Multiple Sclerosis, Merck Patent GmbH, EP3713582A1

Merck Patent GmbH has been granted patent protection for a cladribine-based regimen for treating progressive forms of multiple sclerosis. The patent application EP3713582A1 was published on April 15, 2026, designating 32 states including major European markets. Inventors include DOTZAUER, Matthias and DANGOND, Fernando. The patent claims cover pharmaceutical compositions and methods using cladribine (A61K 31/7076) for neurological applications (A61P 25/00).

RGMA Binding Protein and Use Thereof - Tanabe Pharma, EP3584260A1

The European Patent Office published patent application EP3584260A1 on April 15, 2026, covering RGMA (Glass-like Rolling Membrane Protein A) binding proteins and their therapeutic uses. The patent names Tanabe Pharma Corporation, Osaka University, and National University Corporation Chiba University as applicants, with inventors HASHIMOTO Motonori and YAMASHITA Toshihide. The invention is classified under A61P 25/00 (nervous system diseases) and A61P 37/02 (immunological disorders), covering therapeutic applications in neurological and immunological disease treatment.

Bristol-Myers Squibb Benzodiazepinone Patent EP3793563A1 Published April 15

EPO published application EP3793563A1 for Bristol-Myers Squibb Company and Ayala Pharmaceuticals Inc., covering compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use. The application, published April 15, 2026, is classified under IPC A61K 31/5513, C07D 243/24, A61P 35/00, and A61K 45/06, indicating pharmaceutical applications including oncology. The application designates all EPO member states and several additional European countries, including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR. Named inventors are FISCHER, Bruce S., BAJAJ, Gaurav, and SIDRANSKY, David.

Oncternal Therapeutics SARD Ligands Cancer Treatment Patent Published

European Patent Application EP3793541A1 was published by the European Patent Office on April 15, 2026, covering selective androgen receptor degrader (SARD) ligand compounds and methods of use for cancer treatment. The patent application names Oncternal Therapeutics, Inc. and the University of Tennessee Research Foundation as applicants, with five named inventors. The designated states cover all EPC contracting states including AT, BE, DE, FR, GB, IT, NL, ES, SE, and 21 others.

HBD2 Therapeutic Patent for Preterm NEC, Apr 15

EPO published patent application EP3706773A2 titled 'HBD2 FOR USE IN THE TREATMENT OF NECROTISING ENTEROCOLITIS IN A PRETERM INFANT' on April 15, 2026. The applicant is Defensin Therapeutics ApS with inventor Peter Nordkild. The application covers the therapeutic use of HBD2 (human beta-defensin 2) for treating necrotizing enterocolitis in preterm infants. The designated states cover all major European patent convention member states including DE, FR, GB, IT, NL, SE, and others.

Bisfluoroalkyl Benzodiazepinone Combination Patent Application by Ayala Pharma

The EPO published patent application EP3790552A1 filed by Ayala Pharmaceuticals Inc. covering bisfluoroalkyl-1,4-benzodiazepinone compounds and combination compositions for therapeutic use. The application is classified under A61P 35/00 (antineoplastic agents) and A61P 35/02 (leukemia), indicating oncology as the intended therapeutic indication. The publication is designated across all European Patent Convention contracting states including DE, FR, GB, IT, ES, NL, BE, CH, SE, and 27 others. This A1 publication establishes the application's filing date and makes the technical disclosure publicly available for opposition purposes.

Vaccine Molecules, University of Oslo, EP3678699A1

The European Patent Office published application EP3678699A1 on April 15, 2026, covering vaccine molecules. The application was filed by the University of Oslo with inventors Gunnveig GRODELAND, Bjarne BOGEN, and Anne Marie ANDERSON. The invention is classified under IPC A61K 39/145 (influenza vaccines), C07K 16/28, C07K 16/44, C07K 14/11, and therapeutic application A61P 31/16. The application designates 31 European and associated states including Germany, France, the United Kingdom, and Italy.

Cancer Stem Cell-Specific Molecule EP3603671A2, Chugai, Apr 15

The European Patent Office published patent application EP3603671A2 by Chugai Seiyaku Kabushiki Kaisha on April 15, 2026, covering cancer stem cell-specific molecules including antibodies, compositions, and methods for cancer detection and treatment. The application is published under the A2 designation, indicating international application with international search report. Designated states cover all current EPO member states and extension states across Europe.

Novel Multitarget Drug for Treating Diseases in Mammals (EP3632424A1)

The EPO published application EP3632424A1, filed by Pharmenterprises Eurasia LLC, covering a novel multitarget drug composition for treating diseases in mammals. Inventors listed are Nebolsin Vladimir Evgenievich, Kromova Tatyana Alexandrovna, and Rydlovskaya Anastasia Vladimirovna. The application carries IPC classifications including A61K 31/223 (amino acid derivatives) and is designated across 33 European states. Patent rights are enforceable upon grant, with the 18-month publication window providing third parties opportunity to review and oppose.

Upadacitinib versus Infliximab Acute Severe Ulcerative Colitis Second-Line Treatment

A Phase 4 clinical trial (NCT07550673) is registered on ClinicalTrials.gov evaluating upadacitinib versus infliximab as second-line treatment for acute severe ulcerative colitis. The study title indicates a comparative effectiveness evaluation of these two biologic therapies for patients who have not responded to initial treatment. Trial details including eligibility criteria, enrollment status, and study locations can be accessed through the ClinicalTrials.gov registry.

Compression vs Antibiotics, 25 French Sites, Erysipelas Study

This ClinicalTrials.gov registry entry documents a Phase 4 interventional study (NCT07549594) comparing compression therapy versus antibiotic treatment for erysipelas (cellulitis), a bacterial skin infection. The randomized, open-label, parallel-assignment trial is being conducted across 25 clinical sites in France and is registered under NIH's clinical trials database.

Intraosseous Antibiotic Prophylaxis in Hip Replacement, Somerset, NJ

A Phase 4 clinical trial (NCT07549542) has been registered on ClinicalTrials.gov investigating intraosseous antibiotic prophylaxis in hip replacement surgery. The trial is being conducted in Somerset, New Jersey. This registry entry provides information about the study's purpose and location but contains limited detail about the study protocol, enrollment criteria, or outcomes.

CSF Shunt Infection, Children, Asyut, Egypt

This ClinicalTrials.gov entry documents a Phase 4 clinical trial (NCT07547826) registered by NIH focused on CSF shunt infection in pediatric patients. The trial is being conducted in Asyut, Egypt, and is catalogued in the Phase 4 trial database. No substantive study description, eligibility criteria, or outcome measures are visible in the available registry record. This is a routine registration entry providing basic trial identification information.

Phase 4 Opioid Use Disorder Trial in Vancouver, Canada

ClinicalTrials.gov has registered a Phase 4 clinical trial (NCT07546396) investigating a treatment for opioid use disorder, with the trial site located in Vancouver, Canada. The registration provides a structured card-format summary of the trial including its phase classification, therapeutic area, and geographic location. This entry represents the current indexed record in the ClinicalTrials.gov database as of the posted update date.

Dexmedetomidine, Myocardial Protection, Zhejiang, Phase 4

A Phase 4 clinical trial investigating dexmedetomidine for myocardial protection has been registered on ClinicalTrials.gov under NCT07549282. The trial is being conducted in Zhejiang, China, and is categorised under the drug dexmedetomidine hydrochloride. ClinicalTrials.gov serves as the clinical trial registration database for the National Library of Medicine, operating under NIH authority.

Myofascial Pain Trial, Trapezius Trigger Points, Kyrenia Cyprus

A Phase 4 clinical trial investigating myofascial pain syndrome associated with trapezius muscle trigger points has been registered on ClinicalTrials.gov. The trial, identified as NCT07547605, is being conducted in Kyrenia, Cyprus. Healthcare providers and clinical investigators should be aware of this ongoing research in the myofascial pain field.

FDA Annual Postmarket Drug Study Reports

FDA publishes annual Federal Register notices summarizing data from its internal PMR/PMC databases, which track the status of postmarketing requirements (PMRs) and postmarketing commitments (PMCs) that manufacturers must conduct for certain approved drug and biological products. This resource page provides links to annual reports from FY 2005 through FY 2024, covering CDER and CBER data together, along with a supplementary report for FY 2013-2014 describing CDER's internal evaluation and data-quality efforts.

FDA GDUFA IV Reauthorization for Fiscal Years 2028-2032

FDA is preparing for the fourth reauthorization of the Generic Drug User Fee Amendments (GDUFA) covering fiscal years 2028-2032. The current GDUFA III legislative authority, enacted under the FDA User Fee Reauthorization Act of 2022, expires in September 2027, requiring new legislation for FDA to continue collecting generic drug user fees. FDA hosted a public kickoff meeting on July 11, 2025, and has conducted multiple industry and stakeholder discussion sessions documented through March 2026 covering topics including fee structures, ANDA process improvements, facility inspections, and drug master files.

GDUFA III User Fee Rates FY 2025–2026

The FDA's Generic Drug User Fee Amendments (GDUFA III) program remains reauthorized through September 30, 2027. FY 2026 user fees include ANDA fees of $358,247 (up from $321,920 in FY 2025), DMF fees of $102,584, and program fees scaled by portfolio size from $191,838 (small) to $1,918,377 (large). Facility fees range from $43,549 (domestic API) to $253,943 (foreign FDF). Beginning October 1, 2025, FDA will no longer accept paper-based payments; all payments must be made by electronic check, credit card, or wire transfer.

FDA Updates OMUFA Arrears and Paid Facilities Lists with FY2026 Fee Rates

FDA published updated over-the-counter (OTC) Monograph Drug User Fee Program (OMUFA) arrears and paid facilities lists on April 8, 2026, and published the OMUFA facility fee rates for FY 2026 on March 18, 2026 in a Federal Register notice. Facility fees decreased substantially: the Monograph Drug Facility (MDF) Fee dropped from $37,556 (FY 2025) to $19,188 (FY 2026), and the Contract Manufacturing Organization (CMO) Fee fell from $25,037 to $12,792. OMOR Tier 1 fees rose from $559,777 to $587,529, and OMOR Tier 2 fees increased from $111,955 to $117,505. The OMUFA II reauthorization was signed into law on November 12, 2025 (Public Law No. 119-37), extending the program through FY 2030.

Music Therapy, Breathing Exercises, and Virtual Reality for Obstetric Recovery After Cesarean Section

This clinical trial registration describes a randomized controlled study evaluating three non-pharmacological interventions—music therapy, breathing exercises, and virtual reality—for improving obstetric recovery, pain management, and gastrointestinal symptoms following cesarean section. The trial targets women undergoing cesarean delivery and will assess relaxation effects, parasympathetic activity enhancement, pain perception reduction, and overall postpartum well-being. Conditions studied include cesarean section pain and delayed gastrointestinal function.

Oncology Acute Care Follow-up Intervention Study, Parkland Health, NCT07550192

This pragmatic randomized controlled trial (NCT07550192) evaluates an education intervention designed to increase patient engagement with Oncology Acute Care (OAC) services among cancer patients at Parkland Health. Patients are randomized to control (usual care) or intervention arms, with the intervention receiving automated MyChart messages and texts at 24, 48, and 72 hours post-discharge. Follow-up occurs at 3-month intervals until an outcome is documented.

NCT07551440: Pilot Observational Study of Gastric Cancer Metastases

A pilot observational study (NCT07551440) titled 'Identification of Therapeutic Targets in Metastatic Gastric Cancer' was registered on April 24, 2026. The study aims to identify novel therapeutic molecular targets in patients diagnosed with gastric cancer with lymph node or distant metastases. All eligible patients will be screened at the Prince of Wales Hospital. The study is registered as an observational study with conditions listed as Stomach Neoplasms, Benign. This is a clinical trial registry entry providing public access to study information as required by clinical research registration standards.

Phase 1 Gemcitabine and Nab-Paclitaxel With or Without Pitavastatin for Unresectable Pancreatic Adenocarcinoma

A Phase 1, open-label clinical trial (NCT07549958) is evaluating the recommended Phase 2 dose of Gemcitabine with Nab-paclitaxel, with or without Pitavastatin, in subjects with unresectable pancreatic adenocarcinoma (uPDAC). Subjects must already be receiving Gemcitabine for treatment of their disease. The trial studies two conditions: pancreatic cancer and pancreatic cancer metastatic. The study was posted on April 24, 2026.

Cataract Phacoemulsification Study, Postoperative Outcomes, 24th Apr

An observational clinical study (NCT07550907) was registered on ClinicalTrials.gov examining the impact of phacoemulsification tip location during cataract surgery on early postoperative corneal changes and visual acuity outcomes. The study will enroll patients with age-related cataracts and use intraoperative OCT imaging to evaluate tip positioning across three locations (supracapsular, iris-lens diaphragm, and endocapsular). The registration documents the study protocol and outcome measures without creating any regulatory obligations.

Foot Reflexology in Neonates With Hypoxic-Ischemic Encephalopathy (NCT07549789)

This is a ClinicalTrials.gov registry entry for a randomized controlled trial (NCT07549789) evaluating foot reflexology as an intervention in neonates diagnosed with hypoxic-ischemic encephalopathy who are undergoing therapeutic hypothermia. The study will compare comfort levels and physiological parameters between neonates receiving standardized foot reflexology sessions plus routine care versus routine care alone. The trial is registered with an anticipated status date of April 24, 2026.

HS-10380 Phase 2b Schizophrenia Efficacy Trial, Hospitalized Adults

This ClinicalTrials.gov registry entry documents a Phase 2b randomized, double-blind, parallel-group, active-controlled and placebo-controlled multicenter inpatient study (NCT07550387) evaluating HS-10380 in adult patients with DSM-5 schizophrenia who are acutely psychotic. The study employs three HS-10380 dose arms (Low, Medium, High) alongside an Aripiprazole active comparator and placebo. The primary endpoint is reduction in Positive and Negative Syndrome Scale (PANSS) total scores versus placebo; secondary endpoints include response rate, symptom improvement, safety, tolerability, and pharmacokinetics. As a registry entry, this document does not create compliance obligations but informs pharmaceutical manufacturers and investors about a drug candidate in early clinical development.

HBM-Based Solution-Focused Birth Program for Fear of Childbirth in Primigravidas

This ClinicalTrials.gov record (NCT07549204) registers a randomized controlled trial evaluating a Health Belief Model-based solution-focused childbirth preparation education program against standard antenatal care, targeting fear of childbirth (tokophobia) in first-time pregnant women. The four-year trial will enroll participants in intervention and control groups, measuring fear levels, belief in normal birth, pregnancy-related stress, and delivery mode as outcomes. Findings are intended to inform maternal psychological well-being interventions and positive childbirth experience strategies.

PEMF Therapy in Shoulder Tendinopathy - NCT07550543

This ClinicalTrials.gov registry entry documents a randomized controlled trial evaluating whether pulsed electromagnetic field (PEMF) therapy via the Super Inductive System (SIS), added to a multimodal rehabilitation program, improves pain, function, pressure pain threshold, muscle strength, psychological status, and quality of life in adults with shoulder tendinopathies. The study will compare participants receiving standard balneophysiotherapy against those receiving the same treatment supplemented with PEMF (SIS) therapy. Evaluations occur at baseline, discharge, and 4 weeks post-treatment using validated clinical instruments.

Basement Membrane Regeneration Wound Repair Observational Study

This document registers a prospective, multicenter, observational study (NCT07551284) evaluating autologous basement membrane regeneration technology for wound repair in 1,000 patients across multiple hospitals in China. The study will compare 500 patients receiving the cell suspension therapy combined with standard surgical procedures against 500 matched patients receiving standard procedures alone, with primary outcomes including complete wound healing rate at 4 weeks and time to complete wound closure, followed for up to 6 months.

B·R·A·H·M·S PlGF Plus Kryptor Safety Notice - ANSM R2609954

ANSM has published a safety notice (ref. R2609954) regarding a safety action implemented by Brahms (Thermo Fisher Scientific) on the B·R·A·H·M·S PlGF Plus Kryptor diagnostic reagent used in medical biology laboratories. The safety action letter, dated 24/04/2026, has been distributed to affected users. ANSM directs inquiries to the manufacturer Brahms directly.

Epoc BGEM BUN Test Cards Recall R2611086 - Medical Biology Laboratories

ANSM recorded safety action R2611086 after Epocal withdrew multiple lots of Epoc BGEM BUN Test Cards (boxes of 25 test cards) from medical biology analysis laboratories. The recalling firm has directly notified affected users. The safety alert is registered under ANSM reference R2611086. Laboratories in possession of the recalled product should contact Epocal directly for instructions.

Balloon-Expandable Heart Valve System - EP4149394A1, Vitae LLC

The European Patent Office published patent application EP4149394A1 for a balloon-expandable heart valve system and method of implantation filed by Vitae LLC. The application names TIAN, Bin as the sole inventor and falls under IPC classification A61F 2/24 (heart valve prostheses). The publication designates 32 European states where patent protection may eventually be sought. This is an A1 publication — the application has been made publicly available but has not yet been granted.

Knee Prosthetic Planning System, EP4153044A1, Apr 15

The European Patent Office published patent application EP4153044A1 for a knee prosthetic planning system filed by Little Engine, LLC. The application names five inventors and covers IPC classifications related to prosthetic devices, including A61B 5/103, A61F 2/08, and A61F 2/38. The designated states cover all major European patent validation countries including Germany, France, the United Kingdom, Italy, Spain, and the Netherlands.

Method for Producing an Orthopaedic Support Element, Patent EP4188288A1

The European Patent Office has granted patent EP4188288A1 titled 'Method for Producing an Orthopaedic Support Element' to inventor-applicant David Hahlbrock. The patent covers production methods for orthopaedic support elements classified under IPC A61F 5/01 (orthopaedic apparatus) and A61F 5/02 (orthopaedic devices), with additional classification under B29C 33/38 (moulding processes). The granted patent is valid in 32 designated contracting states including Germany, France, the United Kingdom, Italy, and other EPO member states.

Medtronic Balloon-Expandable Cardiac Valve Prosthesis Stent Patent EP4114311A1

The European Patent Office published EP4114311A1, a patent application filed by Medtronic, Inc. covering balloon-expandable stents with lengthened commissure posts designed for transcatheter implantation of cardiac valve prostheses. The patent names 17 inventors including Peterson, Kari, Javani, Farrar, Askari, and others, and was published under IPC classification A61F 2/24 on April 15, 2026. The application designates all European member states covered by the EPO.

Oblong Endoscope Sheath, A61B, 15th Apr

European patent application EP3821786A1 titled "Oblong Endoscope Sheath" was published by the EPO on April 15, 2026, with applicants Gyrus ACMI, Inc. d/b/a Olympus Surgical Technologies America and inventors KONOSTRUM, Gregory S., CHENG, Ming J., and GOLDBERG, Daniel R. The application is classified under IPC A61B 1/00, A61B 1/015, and A61B 1/12, covering diagnostic and surgical instruments. The patent is validated in 31 designated contracting and extension states across Europe.

Roche Diabetes Care Patent for Analyte Sensor Electrode Manufacturing

The European Patent Office published patent application EP4000517A1, filed by Roche Diabetes Care GmbH and F. Hoffmann-La Roche AG, covering a method for manufacturing a working electrode of an analyte sensor. The inventors are listed as Branislav Babic and Alexander Steck. The patent application was published on April 15, 2026 and designates multiple European states. This is a routine patent publication event and does not create compliance obligations for third parties.